Moderna stock: Phase 3 melanoma data strengthen oncology case

Moderna and Merck released detailed Phase 3 results on Thursday, October 22, 2026, for their personalized mRNA cancer vaccine intismeran autogene. The study found that combining the vaccine with Merck's Keytruda reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone, according to CNBC.

Moderna stock traded at 195.86 euros on Lang & Schwarz at 11:41 CET on Friday, October 30, 2026. The quote gives investors a current trading reference as the market assesses the program's commercial and regulatory potential.

Phase 3 results strengthen oncology case

The INTerpath-001 trial enrolled about 1,100 patients whose melanoma tumors had been surgically removed. Alongside the primary result, the combination cut the risk of distant cancer spread or death by 38% compared with Keytruda alone. The companies also reported that the combination group had an 82.2% recurrence-free rate at two years, versus 70% for the Keytruda-only group.

The treatment is designed for patients after surgery and uses tumor-specific mutations to train the immune system to recognize residual cancer cells. CNBC quoted six melanoma specialists who viewed the findings as a clinically meaningful advance, although the report also noted that the study does not establish whether this approach is more effective than immunotherapy given before surgery.

A separate analysis showed a 58% reduction in the risk of recurrence or death after the six-month treatment point. The overall 42% result remains the primary analysis, based on a median follow-up of about two years. Moderna CEO Stephane Bancel told CNBC that the company was finishing a regulatory filing and aimed for approval next year.

Commercial hurdles remain ahead

The clinical results do not remove the execution challenges. Each vaccine is customized for an individual tumor, and the manufacturing process can take several weeks. Physicians cited by CNBC also said that the treatment could be used mainly after surgery, while patients receiving immunotherapy before surgery may continue with that established pathway.

Moderna is seeking to reduce its dependence on Covid products by expanding into oncology and other disease areas. The melanoma program is a significant validation of that strategy, but success in melanoma does not guarantee comparable results in lung, bladder or kidney cancer. The eventual market opportunity will also depend on regulatory review, manufacturing capacity, reimbursement and the durability of the clinical benefit.

The wider US equity market is the relevant backdrop for Moderna investors: Current market reports.

Moderna is expected to report third-quarter results on November 6, 2026. View the real-time quote of Moderna Inc stock and find More news and analyses on Moderna Inc stock.